MARKET

CLYM

CLYM

Climb Bio
NASDAQ
11.66
-0.23
-1.93%
After Hours: 11.66 0 0.00% 19:30 09/25 EDT
OPEN
11.89
PREV CLOSE
11.89
HIGH
11.92
LOW
11.53
VOLUME
1.53M
TURNOVER
--
52 WEEK HIGH
18.33
52 WEEK LOW
1.540
MARKET CAP
669.71M
P/E (TTM)
-14.1368
1D
5D
1M
3M
1Y
5Y
1D
Climb Bio added to ‘Analysts Current Favorites’ at Raymond James
TipRanks · 2d ago
Weekly Report: what happened at CLYM last week (0914-0918)?
Weekly Report · 4d ago
10 small-cap healthcare stocks with the strongest momentum grades
Seeking Alpha · 09/17 14:20
Small-cap stocks with strong momentum grades and triple-digit YTD gains
Seeking Alpha · 09/17 13:55
Weekly Report: what happened at CLYM last week (0907-0911)?
Weekly Report · 09/14 09:45
Climb Bio Is Maintained at Outperform by Oppenheimer
Dow Jones · 09/08 17:05
Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25
Benzinga · 09/08 16:55
Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 09/08 13:07
More
About CLYM
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that address significant unmet need for patients living with immune-mediated diseases. Its lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells. By targeting CD19, budoprutug has the potential to provide reductions in B cells and pathogenic autoantibodies. The Company is developing budoprutug for the treatment of primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). The Company is in Phase II clinical trial of budoprutug for pMN, Phase Ib/IIa clinical trial for ITP, and Phase Ib clinical trial of budoprutug for SLE. The Company is also developing CLYM116, an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody being developed for the treatment of immunoglobulin A nephropathy.

Webull offers Climb Bio Inc stock information, including NASDAQ: CLYM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLYM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLYM stock methods without spending real money on the virtual paper trading platform.